Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

ies for the use of the Company's technology to evaluate compounds. This effort resulted in contracts including two with Centocor, Inc.
  • The Company entered into a royalty agreement with Concordia Pharmaceuticals to realize the potential upside value of Salirasib, Concordia's novel compound for the treatment of cancer, in combination with another targeted drug.
  • The Company established collaboration with Gradalis Inc. and Mary Crowley Medical Research Center to develop personalized vaccines for cancer patients through the use of the Biomerk Tumorgraft technology.
  • The Company grew the number of procedures within its Personalized Oncology business by 33% and has initiated processes to make this service more readily available in key international markets.
  • The Company continued to expand initiatives to develop its own drug pipeline. During the quarter numerous candidates were identified, due-diligence was performed, and the Company is currently in negotiations for acquisition or co-development of a number of agents.
  • For more information regarding Champions Biotechnology please visit our web site at www.championsbiotechnology.com.

    About Champions Biotechnology, Inc.

    Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their response to drugs is predicti
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
    2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
    3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
    4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
    5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
    6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
    7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
    8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
    9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
    10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
    11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
    (Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
    (Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
    (Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
    Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
    ... law firm of Finkelstein,Thompson LLP announces that a class ... Court for the Southern District of New York on,behalf ... GPC Biotech AG,("GPC Biotech" or the "Company") (Nasdaq: ... inclusive (the "Class Period"). Finkelstein Thompson LLP,is investigating similar ...
    ... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that Oncoscience ... of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has advised ... commence in Europe. - A ...
    ... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... shareholders today that the Annual General Meeting ... been postponed due the geographical,nature of its ... of,proxy materials. The Company is currently working ...
    Cached Biology Technology:Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Sinovac Announces Postponement of Annual General Meeting 2
    (Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
    (Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
    (Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
    Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
    ... Stanford University research team has been awarded $6.27 million ... to be more energy efficient at home. The funding, ... U.S. Department of Energy,s Advanced Research Projects Agency-Energy (ARPA-E), ... come from Stanford and the California Energy Commission. ...
    ... skeleton made of segments, the vertebrae. During development of the embryo, ... head-end to the tail-end: the first segments to be added become ... ribs and the last ones the vertebra located in the tail ... it is crucial that, on the one hand, each segment, as ...
    ... October 27 2009 - The Government of Nepal announced today ... Landscape by 900 sq km, which will increase critical habitat ... at the inaugural session of the Kathmandu Global Tiger Workshop. ... government would establish a National Tiger Conservation Authority as well ...
    Cached Biology News:Stanford researchers awarded $6.27 million to study energy efficiency and human behavior 2The skeleton: Size matters 2Nepal expands critical tiger habitat 2
    ... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
    ... polyclonal to JNK1 (phospho T183 + Y185) ... domain containing phosphorylated T183/Y185. Reactivity / Specificity ... yet tested in other species. Background Information ... the ERK, JNK, and p38 kinases. The members ...
    ... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
    ... been designed to provide a thin film-like barrier when ... slide. This barrier creates the proper surface tension ... on the slide. PAP Pen contains a special ... It can be removed, if desired, by xylene after ...
    Biology Products: